2025 COMB丨Professor Fei Ma: New Perspectives in Breast Cancer Immunotherapy—Mechanistic Insights, Adverse Event Management, and Precision Pathways
Editor’s Note: Immunotherapy has become an important treatment modality in breast cancer, achieving breakthroughs by modulating the immune system to mount anti-tumor responses. At the 8th Conference on Oncology Precision…
EBMT President-Elect Professor Ibrahim Yakoub-Agha: Allogeneic Hematopoietic Stem Cell Transplantation for Myeloproliferative Neoplasms
Editor’s Note: The 13th Lu Daopei Hematology Forum, jointly organized by the Beijing Health Promotion Association and the Guangzhou Hongmian Cancer and Rare Disease Foundation and hosted by the Beijing…
2025 COMB丨Professor Jiayu Wang: Balancing Individualized Treatment and Liver Function Preservation in Breast Cancer Liver Metastases
Editor’s Note: Breast cancer liver metastases represent a major clinical challenge, requiring treatment strategies that balance anti-tumor efficacy with protection of liver function. At the 8th Conference on Oncology Precision…
Professor Bing Han: Treatment Strategies for Aplastic Anemia in the TPO-RA Era
Editor’s Note: The 13th Ludaopei Hematology Academic Conference, jointly organized by the Beijing Health Promotion Association and the Hongmian Tumor and Rare Disease Public Welfare Foundation, and hosted by the…
Professor Robert Negrin, ASH President-Elect: Immunoregulatory Mechanisms to Improve Transplant Outcomes
Editor’s Note: The 13th Ludaopei Hematology Academic Conference, jointly organized by the Beijing Health Promotion Association and the Guangzhou Hongmian Tumor and Rare Disease Public Welfare Foundation and hosted by…
Professor Jinchun Xing: Advances and Future Perspectives in the Diagnosis and Treatment of Urothelial Carcinoma | 2025 Pujiang Uro-Oncology Conference
Urothelial carcinoma (UC) is a highly aggressive malignancy with high incidence and severe complications, significantly impacting patients’ quality of life and survival outcomes. In recent years, there have been remarkable advances in both the diagnosis and treatment of UC. At the 2025 Pujiang Uro-Oncology Conference—jointly organized by the CSCO Urothelial Carcinoma Expert Committee, CSCO Renal Cancer Expert Committee, the Chinese Urologic Oncology Cooperative Group, the Beijing Health Promotion Association Chen Jumei Public Welfare Foundation, and the Shanghai Urologic Oncology Institute, and co-organized by Fudan University Cancer Hospital—Professor Jinchun Xing of the First Affiliated Hospital of Xiamen University delivered an insightful lecture on the latest breakthroughs and future directions in UC management.
Professor Zhuowei Liu: Pioneering a New Paradigm in Urothelial Carcinoma Treatment – From Surgical Innovations to Mechanistic Insights | 2025 Pujiang Uro-Oncology Conference
At the recently concluded 2025 Pujiang Uro-Oncology Conference, the “High-Quality Development Forum on Urologic Oncology” drew considerable attention as leading domestic and international experts shared cutting-edge clinical and translational research progress. Professor Zhuowei Liu from Sun Yat-sen University Cancer Center (SYSUCC) was invited to present his team’s series of innovative studies in the field of urothelial carcinoma (UC). His talk systematically showcased how investigator-initiated trials (IITs)—ranging from refinements in radical surgery to mechanistic studies of therapeutic resistance—are driving meaningful change in clinical practice and advancing the field.